Rally to Support Cancer Research Today

by Robert Levy

More than 18,000 cancer scientists from around the world are in Washington, D.C., this week for the annual meeting of the American Association for Cancer Research (AACR). The meeting serves as a forum for the presentation and discussion of the latest discoveries in cancer research.

The meeting coincides with the Rally for Medical Research, which was held Monday morning on the steps of the Carnegie Library in the nation’s capital.

Dana-Farber's Judy Garber, MD

Judy Garber, M.D., Director, Center for Cancer Genetics and Prevention at Dana-Farber Cancer Institute

Thousands of advocates, cancer survivors, researchers, caregivers, business leaders, and members of the general public gathered to support sustained funding for the National Institutes of Health (NIH), the country’s largest funder of health-related research. Dana-Farber researchers Ken Anderson, MDJudy Garber, MD, MPH; William Hahn, MD, PhD; and Kornelia Polyak, MD, PhD, were there. The rally was also streamed live on YouTube.

At the AACR meeting, more than 6,000 researchers are presenting their findings. Some of the important discoveries from Dana-Farber researchers include:

A new blood test revealed more of the important gene mutations within certain digestive-tract cancers than did the traditional method of analyzing DNA in small bits of tumor tissue. The test, studied in patients with gastrointestinal stromal tumors, may help doctors identify the full range of mutations to be attacked with targeted therapies.

A drug-and-antibody tandem showed promise in a phase 1 clinical trial involving patients with a drug-resistant form of ovarian cancer. The two-agent compound offers a way to deliver the drug directly to cancer cells with potentially less harm to healthy tissues and organs.

A novel combination of two drugs showed anticancer activity in patients who had incurable solid tumors and carried an inherited mutation in their BRCA genes. A phase 1 clinical trial tested the drugs sapacitabine and seliciclib, which kill cancer cells by damaging their DNA and interfering with their ability to repair it.


Comments Sort By Newest

Leave a Reply

Your email address will not be published. Required fields are marked *

Blue Captcha Image


Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
From young patient to college student, Hannah has been all smiles with the support of her family and caregivers:… https://t.co/oSxMljQOyZ
Dana-Farber @danafarber
Congratulations to Scott Armstrong, MD, PhD, and Alan D’Andrea, MD, on their election to @theNAMedicine.… https://t.co/Ff9JYnG3uB
Dana-Farber @danafarber
Get your squad involved w/ #CheerforDanaFarber & earn @PatsCheer prizes. Learn more: https://t.co/xPG55AS3TAhttps://t.co/U9lJdKSxSS

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.